Is Bristol-Myers Stock Underperforming the S&P 500?

Core Insights - Bristol-Myers Squibb Company (BMY) is a leading biopharmaceutical firm focused on innovative medicines for serious diseases, particularly in oncology, immunology, cardiovascular conditions, and blood disorders [1] - The company has a market capitalization of approximately $100.3 billion, positioning it in the large-cap category, which includes firms valued at $10 billion or more [2] Financial Performance - Over the past three months, BMY's stock has increased by about 4.3%, underperforming the S&P 500 Index, which returned 5.1% during the same period [3] - The stock reached a 52-week high of $63.33 in March but has since declined by roughly 22.2% [3] - In the last 12 months, BMY's shares have decreased by about 16.2%, and in 2025, they have fallen approximately 13% [4] Technical Analysis - BMY has recently approached its 200-day moving average after being below this level since April, indicating a potential shift in momentum [5] Revenue Challenges - The company faces challenges from generic competition affecting its older blockbuster drugs, including Revlimid, Pomalyst, Sprycel, and Abraxane [6] - In the Q3 earnings update on October 30, management reported a 12% year-over-year decline in revenue from its legacy portfolio, totaling $5.4 billion, primarily due to significant generic erosion in Revlimid [6]